Tag Archives: Innova Biosciences

Technology

Innova Biosciences Develops Site-Specific Bioconjugation Technology

Leave a comment

Innova Biosciences, the inventor of the world’s easiest to use antibody labeling kits, is pleased to announce the launch of a site-specific bioconjugation technology for attaching antibodies to gold nanoparticles.

Lincolnshire, UK, September 05, 2013 – Innova Biosciences, the inventor of the world’s easiest to use antibody labeling kits, is pleased to announce the launch of a site-specific bioconjugation technology for attaching antibodies to gold nanoparticles.

Innova’s core business is ‘bioconjugation’ – the joining of two molecules to form a hybrid ‘conjugate’. Conjugates are used in diagnostic tests in hospitals and research labs around the world and in consumer items such as pregnancy test kits. Traditional methods for producing gold conjugates do not provide any control over the orientation of antibodies on the surface of the gold, which may lead to poor performance. Innova’s latest conjugation kit, InnovaCoat® Gold-Hydrazide, allows antibodies to be conjugated via the Fc region, resulting in functional orientation on the nanoparticle surface and enhanced assay sensitivity.

Commenting on the launch of the new conjugation kit Dr Nick Gee, CEO of Innova Biosciences said: “In clinical diagnostics and point-of-care testing there is a desire for more sensitive detection systems to achieve earlier diagnosis and better treatment outcomes, for the benefit of human and veterinary health. This new product combines InnovaCoat® gold nanoparticle stabilisation technology and antibody orientation technology to enhance the performance of antibody-based diagnostic reagents.”

About Innova Biosciences Limited:
Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova’s business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see www.innovabiosciences.com.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

VolitionRx to use Innova Biosciences’ Biotin Technology in its Epigenetic Research Kits

Leave a comment

In-licensing deal between VolitionRx and UK-based Innova Biosciences helps drive development of novel cancer diagnostics

Oxford, UK, July 24, 2013 – VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences will supply its Lightning-Link® Biotin technology for Volition’s NuQ® epigenetic profiling research kits. The addition of the Lightning-Link technology will help Volition to improve the accuracy of its test, whilst speeding up production of the research kits.

Volition will use Lightning-Link® for biotinylation of antibodies employed in its range of NuQ® ELISA kits available to researchers working in the fields of epigenetics and nucleosome research. Volition is also employing the Lightning-Link technology for development of Nucleosomics®-based clinical tests, including its first blood-based diagnostic test for colorectal cancer. The high yield and enhanced specificity offered by the Lightning-Link® system coupled with simplicity of use provide a significant advantage in the manufacture of Volition’s research and clinical assays.

Cancer diagnosis often requires a series of time consuming tests, with a diagnosis sometimes being made days after specimen removal. This in-licensing deal will assist the company in their development and manufacture of novel, easy to use diagnostic kits.

Dr Jake Micallef, CSO of VolitionRx, says: “We’ve been really impressed with Innova’s products. Their biotin kit is simple to use and proved more durable than many competitors’ kits, and we’ve seen significant improvements in reproducibility since we started to use them regularly. We’re looking forward to continuing to work with the Lightning-Link technology.”

Dr Andy Lane, Executive Director at Innova Biosciences, said, “This deal is another perfect example of how Lightning-Link® is increasingly being used by innovative diagnostic companies like VolitionRx to both maximise R&D output and to simplify the manufacturing process.”

Innova Biosciences invites anyone with an interest in biotinylation to view their website – http://www.innovabiosciences.com/antibody-labeling-kits/biotin-streptavidin/lightning-link-biotin.html

Company and Media Contact
Charlotte McCubbin
Singapore (m): +65 92301938
Email: c.mccubbin@volitionrx.com

Investor Relations Contact: MZ Group
Mark A. McPartland, Senior Vice President
Phone: +1-212-301-7130
Email: markmcp@mzgroup.us
Web: www.mzgroup.us

About VolitionRx:
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. VolitionRx’s development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRX at our website at www.volitionrx.com, on Twitter at http://www.twitter.com/VolitionRx , LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

About Innova Biosciences Limited:
Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova’s business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see www.innovabiosciences.com.

Safe Harbor Statement
Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

AssaysLightning-Link® In-licensing Deal Enhances ImmunoReagents’ Product Offering to the Diagnostic Industry

Leave a comment

ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Innova Biosciences (Cambridge, UK) Lightning-Link® technology for commercial purposes.

Cambridge, UK, May 02, 2013 – ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Innova Biosciences (Cambridge, UK) Lightning-Link® technology for commercial purposes.

Through the commercialisation deal, ImmunoReagents will utilise Innova’s technology for the manufacture of antibody conjugates, taking advantage of the very rapid Lightning-Link conjugation protocol that offers 100% yield with enhanced sensitivity in comparison to traditional methods. Such tools are critical to the diagnostic industry; the licensing deal will allow ImmunoReagents to provide enhanced products to facilitate technology development, whilst simultaneously maintaining an effective supply chain when the diagnostic kits are launched into the market place.

Commenting on the agreement ImmunoReagent’s CEO, Dr Ann Black, said, “ImmunoReagents is constantly searching for new technologies to improve our product base and we are pleased to incorporate Innova’s Lighting-Link technology for antibody conjugation.”

Dr Andy Lane, Executive Director at Innova Biosciences, said, “This deal is a perfect example of how Lightning-Link is increasingly being used by high quality manufacturers to both maximise efficiency and increase their product offerings.”

About ImmunoReagents Inc
ImmunoReagents is a leading global manufacturer of quality antibodies and reagents used in research and in vitro diagnostics. They offer a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species. ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located on NCSU’s Centennial Campus, a 1000 acre advanced technology community for university, government and industrial partners. For more information, please see www.immunoreagents.com.

About Innova Biosciences Limited
Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova’s business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. Innova Biosciences invites anyone with an interest in antibody labeling, flow cytometry, lateral flow assays or any lightning link products to please visit the website at http://www.innovabiosciences.com.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

Innova Biosciences Develops Technology to Increase Sensitivity of Diagnostic Tests

Leave a comment

World healthcare models are continuously facing financial challenges when it comes to providing for an ageing population.

Oxford, UK, February 20, 2013 – World healthcare models are continuously facing financial challenges when it comes to providing for an ageing population. The current models for provision are increasingly questioned with the upward trend in healthcare spending becoming a significant portion of the GDP. One solution to alleviate the ever increasing burden is earlier detection of disease using more accurate and sensitive diagnostic kits.

Innova Biosciences has recently launched a technology called Thunder-Link® which will facilitate the development of diagnostic tests. The innovative technology has been designed to allow non-specialists to engineer oligonucleotide conjugates with ease. Such biomolecule complexes are increasingly used in high-sensitivity diagnostic kits, and are designed to overcome limited sensitivity and linear range often encountered with traditional antibody-enzyme conjugates. Prior to Thunder-Link® such biomolecules were difficult and expensive to develop and required specialist knowledge.

Commenting on the launch Nick Gee, CEO, ‘All of Innova’s products in one way or other are geared towards generating conjugates more easily and quickly and improving assay performance. The launch of the Thunder-Link® range of oligo conjugation products firmly places Innova as a key reagent supplier to the diagnostic industry and will assist in bringing high performance diagnostic kits to market.’

About Innova Biosciences Limited
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are Lightning-Link® and InnovaCoat® technologies that simplify the production of antibody-based reagents. The expanding portfolio of products is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. The company is ISO 9001:2008 certified.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

Innova Biosciences is Proud to Announce Award of ISO 9001:2008 Certification

Leave a comment

Innova Biosciences has had its work processes accredited to internationally recognised quality management system (QMS) standards.

Cambridge, UK, January 16, 2013 – Innova Biosciences the original manufacturer and provider of high quality bioconjugation services, used primarily in research, diagnostics and the biotech industry, announced today that it has recently achieved ISO 9001:2008 certification.

Innova Biosciences has had its work processes accredited to internationally recognised quality management system (QMS) standards. In working towards this, every operational process within Innova Biosciences was analysed and challenged resulting in a more efficient and agile organisation.

Innova Biosciences Executive Director, Andy Lane stated ‘We are extremely proud to obtain ISO 9001:2008 certification, which is an important milestone in the development of the company. It is a significant achievement, but more importantly, demonstrates the commitment to a level of excellence upon which our customers in all sectors can depend. Our attention to quality and continuous improvement of our QMS is reflected in Innova obtaining this accolade.’

About Innova Biosciences Limited;
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are Lightning-Link® and InnovaCoat® technologies that simplify the production of antibody-based reagents. The expanding portfolio of products is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. The company is ISO 9001:2008 certified.

For more information, please see www.innovabiosciences.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

Innova Biosciences appoints Dr Andrew Lane as an Executive Director and Tim Bernard as Chairman of the Board

Leave a comment

Innova Biosciences, inventor of the world’s easiest to use bioconjugation kits, is pleased to announce the appointment of Dr Andrew Lane as a new Executive Director onto its Board.

Cambridge, UK, December 05, 2012 – Innova Biosciences, inventor of the world’s easiest to use bioconjugation kits, is pleased to announce the appointment of Dr Andrew Lane as a new Executive Director onto its Board. In addition, Tim Bernard, a non-executive director with Innova for 4 years, will become the company’s new Chairman.

Andrew has more than eighteen years’ experience in the biotechnology industry and was Managing Director of AbD Serotec in Oxford before joining Innova earlier this year. Andrew has in-depth operational experience, including manufacturing and product development, and has negotiated more than 200 licence and supply agreements with international partners, ranging from universities to major life science businesses.

Discussing the appointment Nick Gee – CEO of Innova Biosciences said ‘I’m delighted to welcome Andy onto the Board. As the company continues to expand, it is essential that we maintain a highly experienced executive team with the skills to deliver our growth objectives. Andy’s background is an ideal fit and I very much look forward to working with him.

Andrew commented – ‘I am very pleased to be joining the Board of Innova Biosciences at this exciting time in their development, and look forward to being able to contribute to their growth. The Lightning-Link® and InnovaCoat® technologies are ground-breaking and are opening up a wide range of opportunities which the company is well positioned to take advantage of’.

About Innova Biosciences Limited
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are Lightning-Link® and InnovaCoat® technologies that simplify the production of antibody-based reagents. The expanding portfolio of products is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see www.innovabiosciences.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

Innova Biosciences signs out-licensing deal with StressMarq Biosciences

Leave a comment

Innova Biosciences , inventor of the world’s easiest to use bioconjugation kits, is pleased to announce that the company has entered into a licensing agreement with StressMarq Biosciences (British Columbia, Canada).

Cambridge, UK, September 26, 2012 – Innova Biosciences (Cambridge, UK), inventor of the world’s easiest to use bioconjugation kits, is pleased to announce that the company has entered into a licensing agreement with StressMarq Biosciences (British Columbia, Canada).

The non-exclusive license will allow StressMarq to use Innova’s unique Lightning-Link® technology for commercial purposes. Through the commercialisation deal, StressMarq will create a novel collection of antibody conjugate research tools for the scientific community, with the ultimate objective being the advancement of pioneering science and to elucidate the molecular abnormalities behind disease states such as cancer or diabetes.

Dr Andy Lane, Licensing Manager at Innova Biosciences, said, “This agreement underlines the attractiveness of the Lightning-Link® technology to specialist antibody companies, who can take advantage of the simplicity of the method combined with 100% yields to rapidly increase their catalogue portfolios. We look forward to working with StressMarq, who have an excellent reputation in the research antibody sector.”

Commenting on the agreement StressMarq’s President, Dr Ariel Louwrier, said, “The unique aspects of the Lightning-Link® technology coupled with the core expertise of StressMarq Biosciences in the heat shock protein, cellular stress, ion channels and transporter areas will allow us to better serve the needs of our customers, covering a whole new host of applications. The demonstrated and proven Lightning-Link® technology is an excellent counterpart to our antibody portfolio.”

About Innova Biosciences Limited;
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are the Lightning-Link® and InnovaCoat™ technologies, which simplify the production of antibody-based reagents. The expanding Lightning-Link® and InnovaCoat™ portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see www.innovabiosciences.com.

About StressMarq Biosciences;
StressMarq Biosciences Inc. is a company based in Victoria, British Columbia, Canada, and encompasses what is probably the most experienced combined commercial and scientific heat shock and cellular stress community worldwide. StressMarq Biosciences provide a range of monoclonal and polyclonal antisera, for various research areas including cellular stress, cell signaling, ion channels and apoptosis. For more information, please see www.stressmarq.com.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

Innova Biosciences Recruits International Licensing Manager

Leave a comment

Innova Biosciences Limited is pleased to announce that Dr Andrew Lane has joined the company as International Licensing Manager.

Lincolnshire, UK, Spetember 05, 2012 – Innova Biosciences Limited (Cambridge, UK) is pleased to announce that Dr Andrew Lane has joined the company as International Licensing Manager.

Andrew brings a wealth of experience having worked in the Biotech industry for more than 18 years. He has negotiated over 200 license and supply agreements on an international basis, with a diverse range of partners including university technology transfer offices, IVD companies and major Life Science businesses. These agreements have been key revenue drivers, generating multi-million pound sales over their lifetime.

Discussing the appointment Nick Gee – CEO of Innova Biosciences said ‘I’m delighted to welcome Andrew to Innova Biosciences. As the company continues to expand, it is essential that we maintain a highly experienced executive team with the skills to deliver our growth objectives. Andrew will play a key role in the advancement and commercialization of Innova’s novel antibody labelling technologies, especially in the diagnostics sector.

Andrew commented – ‘I am very pleased to be joining Innova Biosciences at an exciting time in their development and look forward to helping to support the next phase of their growth founded on award winning products with an increasing range of applications.’

About Innova Biosciences Limited
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are Lightning-Link® and InnovaCoat™ technologies that simplify the production of antibody-based reagents. The expanding Lightning-Link® and InnovaCoat™ portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see http://www.innovabiosciences.com.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Technology

Innova Biosciences Secures Prestigious Development of Prototype Grant from the Technology Strategy Board

Leave a comment

Innova Biosciences, inventor of ‘Lightning-Link®’, the world’s easiest to use antibody labelling technology, is pleased to announce it has been awarded a development of prototype grant circa £210,000 by the Technology Strategy Board

Cambridge, UK, May 14, 2012 – Innova Biosciences (Cambridge, UK), inventor of ‘Lightning-Link®’, the world’s easiest to use antibody labelling technology, is pleased to announce it has been awarded a development of prototype grant circa £210,000 by the Technology Strategy Board, with matched company funding of approximately £250,000, to develop novel nanoparticle products for diagnostics applications.

The growing diagnostic market requires nanoparticles that have been linked to antibodies, but the methods for creating these hybrid reagents are complex. The Technology Strategy Board grant, awarded through its Smart programme, will allow Innova to develop high quality reagents using much simpler linking technologies. The use of nanoparticles in life sciences, including diagnostics, is a high value sector and the award of the grant will extend Innova’s penetration into this industry.

Nick Gee (CEO of Innova Biosciences) comments ‘The award of the grant in such a competitive environment underlines Innova’s excellent track record and its on-going commitment to innovation. We expect that the products and technologies emerging from this new programme will transform the way in which nanoparticle reagents are created in the future.’

About Innova Biosciences Limited
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are Lightning-Link® and InnovaCoat™ technologies that simplify the production of antibody-based reagents. The expanding Lightning-Link® and InnovaCoat™ portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide.

Innova Biosciences would like to invite anyone with an interest in antibody labeling or gold nanoparticles to please visit the website for more information, please see www.innovabiosciences.com

About the Technology Strategy Board:
The Technology Strategy Board is the UK’s innovation agency, working to create economic growth by ensuring that the UK is a global leader in innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

Managed by the Technology Strategy Board, the Smart scheme offers funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge.
http://www.innovateuk.org/deliveringinnovation/smart.ashx

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Science

Innova Biosciences Launches Unique Covalent Gold Nanoparticle Conjugation Kit

Leave a comment

Innova Biosciences, inventor of ‘Lightning-Link®’ the world’s easiest to use antibody labeling technology, is pleased to announce the launch of InnovaCoat™ GOLD: a revolutionary kit for the covalent conjugation of gold nanoparticles to antibodies, proteins and biomolecules.

Cambridge, UK, February 20, 2012 – Innova Biosciences (Cambridge, UK), inventor of ‘Lightning-Link®’ the world’s easiest to use antibody labeling technology, is pleased to announce the launch of InnovaCoat™ GOLD: a revolutionary kit for the covalent conjugation of gold nanoparticles to antibodies, proteins and biomolecules. This innovative new technology provides significant advantages over traditional passive adsorption methods and continues in the tradition of the original Lightning-Link® procedure, offering benefits such as 2 minutes hands-on time, 100% antibody recovery and ready-to-use antibody-gold conjugate in just 15 minutes.

Commenting on the launch of InnovaCoat™ GOLD, Dr Nick Gee (CEO of Innova Biosciences) said: ‘Innova Biosciences is very proud to be recognised globally as the leading provider of high quality, yet remarkably simple, conjugation technologies. Our revolutionary new product, InnovaCoat™ GOLD, is the only technology in existence that enables ultra-stable covalent conjugation of antibodies to gold nanoparticles and it overcomes many of the problems associated with traditional passive adsorption methods. We look forward to supporting scientists and in vitro diagnostics manufacturers with the rapid development and enhancement of gold based diagnostic assays.’

The first kit in this new range is the InnovaCoat™ GOLD 40nm gold particle kit, one of the most popular particle sizes, with other sizes and nanoparticles to follow in the coming months. The launch marks the start of an exciting period for Innova Biosciences that will see multiple new product launches, particularly into the in vitro diagnostics market, and will fortify Innova’s position as the leader in antibody labeling technologies.

About Innova Biosciences Limited: Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business is Lightning-Link®, an innovative technology that simplifies bioconjugation for R&D applications, drug discovery and diagnostics. The expanding Lightning-Link® and InnovaCoat™ portfolio is sold to research laboratories, pharmaceutical companies and biotechnology companies worldwide.

Innova Biosciences invites anyone with an interest in antibody labeling or gold nanoparticle conjugation to please visit their website for further details, www.innovabiosciences.com/gold-conjugation-kits.html

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com